Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from LTR Pharma Limited ( (AU:LTP) ).
LTR Pharma has begun patient recruitment in Australia for a Phase II pharmacokinetic clinical study of SPONTAN, its rapid-acting intranasal spray for erectile dysfunction, marking a key milestone in its clinical development program. The trial will enrol around 27 healthy men across three cohorts, with about half aged 65 and over, to generate prescribing insights for older patients who are often managed with lower doses of oral PDE5 inhibitors such as Viagra and Cialis; initial data are expected in the second quarter of 2026, and the company positions SPONTAN’s fast, predictable intranasal delivery as a potential advantage for this underserved demographic.
More about LTR Pharma Limited
LTR Pharma Limited is a commercial-stage pharmaceutical company specialising in innovative therapies delivered via a proprietary intranasal drug-delivery platform. The company has commercialised rapid-acting intranasal treatment technology in Australia and is progressing regulatory pathways in the US and other key markets. Its lead products, SPONTAN and ROXUS, are fast-acting intranasal sprays for erectile dysfunction, while its pipeline includes OROFLOW, an intranasal candidate for oesophageal motility disorders, reflecting a focus on addressing significant unmet medical needs and improving patient quality of life.
Average Trading Volume: 360,889
Technical Sentiment Signal: Buy
Current Market Cap: A$114.4M
For an in-depth examination of LTP stock, go to TipRanks’ Overview page.